Anti-Embolism Stockings

Global Anti-Embolism Stockings Market to Reach US$973.8 Million by 2030

The global market for Anti-Embolism Stockings estimated at US$770.7 Million in the year 2024, is expected to reach US$973.8 Million by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Calf-Length Anti-Embolism Stockings, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$614.2 Million by the end of the analysis period. Growth in the Thigh-Length Anti-Embolism Stockings segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$210.0 Million While China is Forecast to Grow at 7.5% CAGR

The Anti-Embolism Stockings market in the U.S. is estimated at US$210.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$199.4 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Anti-Embolism Stockings Market – Key Trends & Drivers Summarized

Why Are Anti-Embolism Stockings Becoming a Critical Component of Post-Surgical and Bedridden Patient Care?

Anti-embolism stockings have emerged as a crucial tool in the prevention of venous thromboembolism (VTE), particularly for patients undergoing surgery or confined to bed rest. Designed to apply graduated pressure to the lower limbs, these specialized stockings enhance blood circulation by pushing venous blood back toward the heart, thereby preventing stasis—a key contributor to clot formation. Their role has become especially vital in hospital environments where immobility, whether due to major surgery, trauma, or prolonged recovery, significantly elevates the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). Healthcare providers across disciplines now consider anti-embolism stockings a standard of care for at-risk patients, often using them in combination with anticoagulant therapies to reduce complications. Postoperative patients, especially those recovering from orthopedic, abdominal, or cardiovascular procedures, benefit enormously from their use, as movement may be restricted for days or even weeks. Moreover, they are widely recommended for patients in intensive care units (ICUs), geriatric wards, and rehabilitation centers. As hospitals increasingly focus on patient outcomes and safety metrics, reducing the incidence of hospital-acquired conditions like DVT has become a top priority—thus driving the widespread use of anti-embolism stockings. Their cost-effectiveness, ease of application, and non-invasive nature make them an attractive option for both inpatient and outpatient settings. In many cases, the use of these stockings is mandated by institutional protocols and health insurance providers, further cementing their role in modern preventive medicine.

What Medical and Material Innovations Are Enhancing the Efficacy of Anti-Embolism Stockings?

Recent advances in medical textiles and compression technology are significantly improving the comfort, effectiveness, and compliance associated with anti-embolism stockings. Historically, patient adherence was limited due to discomfort, improper sizing, or difficulty in donning the stockings—issues that have now been addressed through more sophisticated designs and materials. Today’s stockings are made with breathable, hypoallergenic, and antimicrobial fabrics that reduce skin irritation and allow for prolonged wear without compromising hygiene. Graduated compression technology has also evolved, allowing for precise control over pressure levels—typically highest at the ankle and gradually decreasing toward the thigh—to optimize venous return without constricting movement or causing tissue damage. Seamless knitting techniques and ergonomic designs ensure a better anatomical fit, which not only improves therapeutic outcomes but also enhances user comfort. Some stockings now incorporate smart fibers capable of temperature regulation, which is particularly beneficial for long-term wear in varied climates. In addition, color-coded sizing systems and improved elasticity have simplified product selection and reduced the risk of improper usage. Digital tools such as 3D body scanners and mobile apps are being used to assist with accurate fitting, especially in outpatient scenarios. Meanwhile, research is ongoing into sensor-embedded stockings that can monitor venous pressure or movement in real-time, potentially transforming these garments into diagnostic tools as well. These technological innovations are raising the clinical and functional standards of anti-embolism stockings, ensuring better patient adherence, improved outcomes, and expanding their application across a wider spectrum of medical scenarios.

How Are Global Demographic Trends and Healthcare Practices Expanding the Market for Anti-Embolism Stockings?

The global market for anti-embolism stockings is being shaped by macro-level demographic shifts and evolving healthcare delivery models. A key factor is the aging global population, particularly in regions like North America, Europe, and parts of Asia, where the prevalence of age-related venous insufficiency, limited mobility, and surgical interventions is significantly higher. Older adults are more susceptible to VTE, and preventive measures like anti-embolism stockings are increasingly prescribed as part of routine care. Additionally, the growing burden of chronic diseases such as obesity, cardiovascular conditions, and diabetes further increases the risk of blood clots, necessitating proactive interventions. At the same time, the rising frequency of elective surgeries—particularly orthopedic procedures such as knee and hip replacements—has created a steady demand for these products in both hospital and post-discharge settings. The shift toward outpatient surgery and same-day discharge models has heightened the need for patient-managed preventive care, with anti-embolism stockings playing a central role in these protocols. Developing nations are also contributing to market growth as healthcare infrastructure improves and awareness of VTE prevention increases. Public health campaigns and institutional mandates are reinforcing the importance of DVT prophylaxis, especially in surgical and long-term care environments. Insurance reimbursement and bundled care initiatives are further incentivizing the use of cost-effective, non-pharmacological preventive measures. In parallel, online retail channels and e-pharmacies are making these stockings more accessible to consumers seeking at-home medical solutions, supporting their use beyond the clinical setting. Collectively, these demographic and structural shifts are creating sustained, global demand for anti-embolism stockings across multiple levels of care.

What Are the Core Drivers Behind the Rising Adoption of Anti-Embolism Stockings Worldwide?

The growth in the anti-embolism stockings market is driven by several compelling factors grounded in clinical demand, healthcare policy, technological improvement, and consumer behavior. One of the most critical drivers is the increasing incidence of VTE, particularly among hospitalized, post-surgical, and immobile patients—a demographic that continues to expand with rising hospitalization rates and longer life expectancy. Regulatory agencies and professional medical associations have issued guidelines recommending the use of compression therapy as a standard preventive measure, giving the category both medical legitimacy and institutional support. The adoption of evidence-based medicine has led to widespread incorporation of anti-embolism stockings in surgical recovery protocols, with hospitals aiming to reduce complications, readmissions, and associated healthcare costs. Another major driver is the continuous advancement in textile engineering, allowing manufacturers to create stockings that are not only more effective but also more wearable—leading to better patient compliance and satisfaction. The increasing popularity of telehealth and remote patient management is also contributing, as clinicians recommend compression wear for patients recovering at home, especially after orthopedic or cardiovascular procedures. Moreover, the rise in health awareness and proactive wellness behaviors has encouraged consumers to invest in preventive health products like compression stockings even without a direct prescription. Distribution has expanded dramatically, with products now available via pharmacies, online platforms, medical suppliers, and even wellness retailers. Strategic partnerships between healthcare providers and manufacturers, along with educational initiatives aimed at both patients and clinicians, are further driving adoption. These factors—combined with a focus on early intervention, preventive care, and non-invasive treatment options—are cementing the role of anti-embolism stockings as a fundamental component of modern healthcare systems around the world.

SCOPE OF STUDY:

The report analyzes the Anti-Embolism Stockings market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Calf-Length Anti-Embolism Stockings, Thigh-Length Anti-Embolism Stockings); Demography (Men, Women); End-Use (Ambulatory Patients End-Use, Post-operative Patients End-Use, Pregnant Women End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• 3M Company
• B. Braun Melsungen AG
• BSN Medical GmbH
• Cardinal Health Inc.
• Covidien (Medtronic)
• Essity AB
• Halyard Health Inc.
• Kendall (Covidien)
• Lohmann & Rauscher GmbH
• Medline Industries, Inc.
• Mölnlycke Health Care AB
• Paul Hartmann AG
• Prestige Brands Holdings Inc.
• Sanko Medical Co., Ltd.
• Sigvaris AG
• Smith & Nephew plc
• Solidea S.r.l.
• Thermo Fisher Scientific Inc.
• Thuasne Group
• Unomedical (a part of Coloplast)

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.